4.97
price up icon2.47%   0.12
pre-market  Pre-market:  4.96   -0.010   -0.20%
loading
Altimmune Inc stock is traded at $4.97, with a volume of 1.72M. It is up +2.47% in the last 24 hours and down -14.46% over the past month. Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$4.85
Open:
$5
24h Volume:
1.72M
Relative Volume:
0.72
Market Cap:
$338.86M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.0305
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+12.95%
1M Performance:
-14.46%
6M Performance:
-26.04%
1Y Performance:
-34.35%
1-Day Range:
Value
$4.95
$5.225
1-Week Range:
Value
$4.37
$5.225
52-Week Range:
Value
$3.553
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
Name
Altimmune Inc
Name
Phone
(240) 654-1450
Name
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALT
Altimmune Inc
4.97 338.86M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.42 124.91B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.85 60.05B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
594.65 35.88B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.97 29.83B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.13 24.58B 3.81B -644.79M -669.77M -6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Initiated William Blair Mkt Perform
Jan-08-25 Initiated Stifel Buy
Nov-12-24 Initiated UBS Buy
Apr-29-24 Downgrade Guggenheim Buy → Neutral
Jan-24-24 Initiated Goldman Neutral
Mar-22-23 Downgrade Goldman Buy → Neutral
Dec-01-22 Initiated Goldman Buy
Dec-29-21 Resumed Jefferies Buy
Jun-02-21 Initiated H.C. Wainwright Buy
Feb-11-21 Initiated Guggenheim Buy
Dec-14-20 Initiated Jefferies Buy
Nov-12-20 Reiterated B. Riley Securities Buy
Sep-25-20 Initiated B. Riley FBR Buy
Aug-14-20 Initiated Evercore ISI Outperform
Jul-31-20 Initiated Piper Sandler Overweight
Jul-28-20 Initiated JMP Securities Mkt Outperform
Feb-24-20 Resumed ROTH Capital Buy
Jul-19-19 Initiated ROTH Capital Buy
Oct-09-17 Initiated Piper Jaffray Overweight
View All

Altimmune Inc Stock (ALT) Latest News

pulisher
Apr 20, 2025

Trading (ALT) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 11, 2025

Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com

Apr 11, 2025
pulisher
Apr 10, 2025

Altimmune's US$42m Market Cap Fall Books Insider Losses - Yahoo

Apr 10, 2025
pulisher
Apr 09, 2025

Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors - Hunt Scanlon Media

Apr 09, 2025
pulisher
Apr 08, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Canada

Apr 08, 2025
pulisher
Apr 08, 2025

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

Apr 08, 2025
pulisher
Apr 06, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 06, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

H.C. Wainwright maintains Buy rating on Altimmune stock - Investing.com India

Apr 04, 2025
pulisher
Apr 03, 2025

8 Analysts Assess Altimmune: What You Need To Know - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing - TipRanks

Apr 03, 2025
pulisher
Apr 03, 2025

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN

Apr 03, 2025
pulisher
Apr 02, 2025

JMP maintains Altimmune stock target at $25 on Phase 2b optimism - Investing.com

Apr 02, 2025
pulisher
Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mar 31, 2025
pulisher
Mar 28, 2025

Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Mar 28, 2025
pulisher
Mar 22, 2025

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo

Mar 22, 2025
pulisher
Mar 19, 2025

Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey

Mar 19, 2025
pulisher
Mar 17, 2025

Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 16, 2025

Altimmune rises as buyout rumors follow R&D updates - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia

Mar 15, 2025
pulisher
Mar 14, 2025

Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune soars amid takeover speculation - MSN

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha

Mar 14, 2025
pulisher
Mar 14, 2025

(ALT) Trading Advice - Stock Traders Daily

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView

Mar 14, 2025
pulisher
Mar 14, 2025

Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa

Mar 14, 2025
pulisher
Mar 14, 2025

Citizens JMP reiterates Altimmune stock with $25 target - Investing.com

Mar 14, 2025

Altimmune Inc Stock (ALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.13
price down icon 0.69%
$70.80
price down icon 0.62%
$31.69
price down icon 1.55%
$33.23
price up icon 21.50%
$114.83
price up icon 9.70%
biotechnology ONC
$249.13
price down icon 1.44%
Cap:     |  Volume (24h):